This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
26 Feb 2015 | Global | Market Research
Regulatory Trends in the US Pharma/Biotech Industry
Efficiency of the FDA Review Process Expedites Access to Care
This research service focuses on existing therapeutics and product pipeline for the treatment of Parkinsons Disease using Dopamine Replacement Therapies, Dopamine Agonists, MAO-inhibitors, COMT-inhibitors and other pharamcolgical approaches for current global interest. This research service does not cover vaccines. A product and pipeline assessmen...
$1,500.00 -
04 Feb 2015 | Global | Market Research
Vital Signs - The Analysts Perspective - January 2015 Issue
This issue of Vital Signs, released on February 4, 2014, discusses Roches collaboration with Foundation Medicine, Novartis potential anti-aging drug, and DNA Electronics; acquisition of nanoMR, Inc.
$500.00 -
04 Feb 2015 | Global | Market Research
Global CRO Market
Transformation, Developments, Opportunities and Future of CRO Market
This research service presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market. It provides revenue forecasts for CROs globally by phase, therapeutic type, and region. It addresses the major issues and challenges, unmet needs, and emerging trends in the market. Detailed information has been provided on s...
$4,950.00 -
07 Oct 2014 | Global | Market Research
Analysis of the Global Stem Cell Market
The key to Transforming Future of Diagnostic and Therapeutic Medicine
This study investigates the global stem cell market for the period 2013 to 2018. The geographic regions covered in the study are the North America, Europe and APAC, followed by a detailed Asia Pacific Region Analysis, which covers countries such as India, Australia, Thailand, Singapore, South Korea, Malaysia and Japan. The stem cell market is cover...
$3,950.00 -
03 Oct 2014 | Global | Market Research
Vital Signs - Healthcare News - The Analysts Perspective - September 2014 Issue
This issue of Vital Signs, released on October 3, 2014, discusses Merck KGaAs acquisition of Sigma-Aldrich, highlights from the 2014 AACC Meeting, Abbotts CE Mark for FreeStyle® Libre, laboratory developed test (LDT) regulations, and the sale of Fortis Healthcares Singapore subsidiary, RadLink-Asia Pte Ltd, and its arm, RadLink Singapore.
$450.00 -
04 Aug 2014 | Global | Market Research
2014 New Product Innovation Leadership Award in The Point of Care Diagnostics for the Emergency Medicine Industry
$1,500.00 -
04 Aug 2014 | Global | Market Research
Vital Signs - Healthcare News - The Analysts Perspective - July Issue
This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biologys Series A funding round, Roches investment in Stratos Genomics, and Indias cap on drug prices.
$500.00 -
11 Jul 2014 | Global | Market Research
Will Virtual CROs and Integrated Business Models Rule the Road
Insights into the innovative steps taken by CROs and pharmaceutical companies in the race for excellence and low-cost trials
This issue of Vital Signs, released on July 11, 2014, discusses game changing strategies in clinical research, including virtual clinical research organization (CRO) and the integrated business model.
$450.00 -
03 Jul 2014 | Global | Market Research
A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
Antiretroviral Combinations Continue to Transform the Treatment Landscape
This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinica...
$3,950.00 -
01 Jul 2014 | Global | Market Research
Vital Signs - Healthcare News - The Analysts Perspective - June 2014
This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.
$450.00
